Cardiac patients are one step closer to obtaining a medical device that can alert them to a potential Acute Coronary Syndrome (ACS) event, including a heart attack, whether they experience symptoms or not, following recent U.S. Food and Drug Administration (FDA) approval of the AngelMed Guardian® System.
Considered Monmouth County-based Angel Medical Systems’ flagship product, the AngelMed Guardian System is the world’s first implantable cardiac monitor and patient alerting system for ACS.
Read more here.
Considered Monmouth County-based Angel Medical Systems’ flagship product, the AngelMed Guardian System is the world’s first implantable cardiac monitor and patient alerting system for ACS.
Read more here.
